A double-blind, placebo-controlled trial of Symmetrel for five months in Parkinson's Disease was performed. Using a daily living ability rating scale, a significant improvement amongst the less severely affected patients and a highly significant improvement of the severely affected patients receiving the drug was observed.
The improvement of both groups was maintained for the duration of the study.
Get full access to this article
View all access options for this article.
References
1.
BarbeauAMarsHBotezM IJoubertM (1971) Amantadine—HCl (Symmetrel) In the Management of Parkinson's Disease. A double-blind cross-over study. Canadian Medical Association Journal, 105, 1: 42-46
2.
DallosVHeathfieldKStonePAllenF AD (1970) Use of Amantadine in Parkinson's Disease. Result of a double-blind trial. British Medical Journal, 4, 5726: 24-26
JorgensenP BBerginJ DHaasLCunninghamJAKMorahD DPollockMRobinsonR GSpearsG FS (1971) Controlled Trial of Amantadine Hydrochloride in Parkinson's Disease. New Zealand Medical Journal, 73, 468: 263 267
7.
ParkesJ DCalverD MZilkhaK JKnill-JonesR P(1970a) Controlled Trial of Amantadine Hydrochloride in Parkinson's Disease. Lancet1, 7641: 259-62
8.
ParkesJ DZilkhaK JMarsdenPBaxterR CHKnill-JonesR P(1970b) Amantadine Dosage in the Treatment of Parkinson's Disease. Lancet1, 7657: 1130-1133
9.
RaoN SPearceJ (1971) Amantadine in Parkinsonism. An Extended Prospective Trial. Practitioner, 206, 1232: 241-245
10.
SchwabR SEnglandA CJrPoskanzerD CYoungR R (1969) Amantadine in the Treatment of Parkinson's DiseaseJournal of the American Medical Association, 208, 7: 1168-70
11.
Sem-JacobsenC W (1966) The Effect of Medical Therapy on Daily Living Capacity in Parkinson's Disease. Journal of Neurosurgery, 24 Suppl. 349–50
12.
WendelH A (1964) Clinical and Serologie Effects in Influenza of 1-Adamantanaminc HCl: A double-blind Study. Federal Proceedings, 23, 2–1: 387
